Head‐to‐head comparison of two senolytic therapies in a mouse model of tauopathy

Outcomes related to physical and cognitive function were largely unchanged by senolytic in rTg4510 mice, indicating our model may have been too advanced by the time of drug initiation to see benefits from the treatment. Subtle, functional changes observed after senolytic in WT mice and the RNA sequencing data highlight the need for additional studies to evaluate the appropriateness of selected senolytic, dose, and initiation timeline, for use in AD relevant populations.